Cystic Fibrosis Outcomes With Concomitant Azithromycin and Tobramycin Use
Patients with cystic fibrosis who had pulmonary exacerbations treated with concomitant azithromycin and tobramycin had worse outcomes than those treated with tobramycin alone.
Obstructive Lung Disease
Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis
Age may influence outcomes in lung transplant recipients with cystic fibrosis.
CFHealthHub Criteria May Be Useful to Diagnose P Aeruginosa in Cystic Fibrosis
Preliminary evidence suggests that the CFHealthHub criteria are valid and useful in diagnosing chronic Pseudomonas aeruginosa in adults with cystic fibrosis.
Prolonged Heat Exposure in Cystic Fibrosis Can Lead to Metabolic Alkalosis
In patients with cystic fibrosis, prolonged exposure to heat can lead to chloride-deficient metabolic alkalosis as a result of a loss of electrolytes through sweat.
Brensocatib Receives Breakthrough Therapy Status for Non-CF Bronchiectasis
The FDA has granted Breakthrough Therapy designation to brensocatib for the treatment of adults with non-cystic fibrosis bronchiectasis for reducing exacerbations.
Pancreatic Status Affects Lung Function Decline in Adults With Cystic Fibrosis
In adults with cystic fibrosis, pancreatic status — that is, being pancreatic sufficient vs being pancreatic insufficient — has been shown to have a pronounced effect on the average rate of decline in lung function.
Pravibismane Gets Orphan Drug Status for Pulmonary Infections in Cystic Fibrosis
The FDA has granted Orphan Drug designation to pravibismane suspension for inhalation (BisEDT antimicrobial suspension; Microbion) for the management of pulmonary infections in patients with cystic fibrosis.
Tobacco Smoke Exposure Limits Benefits of CFTR Modulators in Cystic Fibrosis
Tobacco smoke exposure inhibited the therapeutic benefit of the cystic fibrosis transmembrane conductance regulator modulators in pediatric patients.
Lumacaftor-Ivacaftor May Improve Glucose Tolerance in Cystic Fibrosis
Patients with cystic fibrosis who were treated for 1 year with a combination of lumacaftor and ivacaftor saw improvements in glucose tolerance abnormalities
Inhaled Messenger RNA Treatment Fast-Tracked for Cystic Fibrosis
The FDA has granted Fast Track designation to MRT5005, an inhaled messenger RNA (mRNA) therapeutic being investigated for the treatment of cystic fibrosis.
-
Loading...
-
Loading...
Next post in Obstructive Lung Disease
